Julie Nixon

The funding will facilitate the business’ growth and expand its commercial presence in the US.

Dxcover Limited is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers.

TLT advised on all aspects of the investment from existing investors Eos Advisory, alongside SIS Ventures, University of Strathclyde, and Norcliffe Capital.

It also involved investment from new investors including Investment Fund for Scotland (IFS) managed by Maven Capital Partners and delivered by the British Business Bank, as well as Macmillan Cancer Support.

Commenting on the investment, managing associate Julie Nixon said: “Dxcover Limited is a business that is pioneering the world of diagnostics and helping save people’s lives. The life sciences sector is one of the largest and most innovative in the world and, overall, has stood out as a beacon of life in the post-Covid economy.”